Clearly, while the refinement of CD36-targeting antibodies requires significant attention, there is increasing interest in CD36 as a potential prognostic for patients with colon, ovarian, breast, small cell lung carcinoma and urinary bladder cancer [29, 43, 44] and melanoma. This evidence concerns the gene CD36 and small cell lung carcinoma.